Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy

Developmental Medicine and Child Neurology

Volumn 49, Issue 11, 2007, Pages 823-829

  Lowe, Kevin ^a   Novak, Iona ^b   Cusick, Anne ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b The Spastic Centre Australia   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARM MOVEMENT; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HEMIPLEGIA; HUMAN; LONGITUDINAL STUDY; MALE; OCCUPATIONAL THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCORING SYSTEM; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; UPPER EXTREMITY;

EID: 35648979980     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2007.00823.x     Document Type: Article

References (34)

1. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. (1997) Botulinum toxin A in the hemiplegic limb: A double-blind trial. Dev Med Child Neurol 39: 185-193.
2. Fehlings D, Rang M, Glazier J, Steele C. (2000) An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 137: 331-337.
3. Friedman A, Diamond M, Johnston MV, Daffner C. (2000) Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 79: 53-59.
4. Boyd R, Bach T, Morris M, Imms C, Johnson L, Graham HK, Syngeniotis A, Abbott D, Jackson G. (2003) A single blind randomized trial of botulinum toxin A (BTX-A) and upper limb training in congenital hemiplegia - activity, participation, and health related quality of life. Dev Med Child Neurol 45 (Suppl. 96): 10-11.
5. Hurvitz EA, Conti GE, Brown SH. (2003) Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch of Phys Med Rehabil 84: 444-454.
6. Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. (2003) Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 82: 284-289.
7. Wallen M, O'Flaherty SJ, Waugh MC. (2004) Functional outcomes of intramuscular botulinum toxin type a in the upper limbs of children with cerebral palsy: A phase II trial. Arch of Phys Med Rehabil 85: 192-200.
8. Speth LA, Leffers P, Janssen-Potten YJM, Vles JSH. (2005) Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 47: 468-473.
9. Lowe K, Novak I, Cusick A. (2006) Low dose/high concentration localised intramuscular botulinum toxin A improves upper limb movement and function in children with cerebral palsy. Dev Med Child Neurol 48: 170-175.
10. Satila H, Kotamaki A, Koivikko M, Autti-Ramo I. (2006) Low- and high-dose botulinum A treatment: A retrospective analysis. Pediatr Neurol 34: 285-290.
11. Novak I, Cusick A, Lowe K. (2007) A pilot study on the impact of occupational therapy home programming for young children with cerebral palsy. Am J Occup Ther 61: 475-480.
12. Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E. (2007) Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: A single blind, randomized controlled trial. Pediatrics 119: 1149-1158.
13. Wallen M, O'Flaherty SJ, Waugh MC. (2007) Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: A randomized controlled trial. Arch Phys Med Rehabil 88: 1-10.
14. Steultjens EM, Dekker J, Bouter, LM, van de Nes JC, Lambregts, BL, van den Ende, CH. (2004) Occupational therapy for children with cerebral palsy: A systematic review. Clin Rehabil 18: 1-14.
15. Reeuwijk A, van Schie PEM, Becher JG, Kwakkel G. (2006) Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: A systematic review. Clin Rehabil 20: 375-387.
16. Schoffer KL, O'Maley K, O'Sullivan JD. (2007) Development and utilization of the patient knowledge questionnaire on botulinum toxin use in movement disorders. J Clin Neurosci 14: 737-741.
17. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. (2006) Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 13 (Suppl 4): 35-40.
18. Papapetropoulos S, Singer C. (2007). Botulinum toxin in movement disorders. Semin Neurol 27: 183-194.
19. Goldstein EM. (2006) Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21: 189-192.
20. Eames NWA, Baker R, Hill N, Graham HK, Taylor T, Cosgrove A. (1999) The effect of botulinum toxin A on gastrocnemius length: Magnitude and duration of response. Dev Med Child Neurol 41: 226-232.
21. Boyd RN, Graham JEA, Nattrass GR, Graham HK. (1999) Medium-term response characterization and risk factor analysis of botulinum toxin type A in the management of spasticity in cerebral palsy. Eur J Neurol 6 (Suppl 4): S37-S45.
22. Kawamura A, Campbell K, Lam-Damji S, Fehlings D. (2007) A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 49: 331-337.
23. DeMatteo C, Law M, Russell D, Pollock N, Rosenbaum P, Walter S. (1992) Quality of Upper Extremity Skills Test. Hamilton, Ontario: Neurodevelopmental Clinical Research Unit Chedoke-McMaster Hospitals.
24. Law M, Baptiste S, Carswell A, McColl M, Polatajko H, Pollock N. (1994) The Canadian Occupational Performance Measure, 2nd edn. Toronto: Canadian Association of Occupational Therapists.
25. Cusick A, Lannin N, Lowe K. (2007) Adapting the Canadian Occupational Performance Measure for use in a paediatric clinical trial. Disabil Rehabil 29: 761-766.
26. Haley M, Coster W, Ludlow L, Haltiwanger J, Andrellos P. (1992) Pediatric Evaluation of Disability Inventory: Development, Standardization and Administration Manual. Boston: New England Medical Center Hospitals Inc.
27. Kiresuk TJ, Smith JE, Cardillo JE. (1994) Goal Attainment Scaling: Applications, Theory and Measurement. Hillsdale, NJ: Lawrence Earlbaum Associates.
28. Ashworth B. (1964) Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 92: 540-542.
29. Lannin N, Scheinberg A, Clark K. (2006) AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 48: 533-539.
30. Larin H. (2000) Motor learning: Theories and strategies for the practitioner. In: Campbell SK, Vander Linden DW, Palisano, RJ, editors. Physical Therapy for Children, 2nd edn. Philadelphia: WB Saunders. p 170-197.
31. Gough M, Fairhurst C, Shortland AP. (2005) Botulinum toxin and cerebral palsy: Time for reflection? Dev Med Child Neurol 47: 709-712.
32. Chen CM, Stott NS, Smith HK. (2002) Effects of botulinum toxin A injection and exercise on growth of juvenile rat gastrocnemius muscle. J Appl Physiol 93: 1437-1447.
33. Pang KK, Quinby JM, Eyre JA, Slater CR. (2004) Long-term effects of botulinum toxin-A in semimembranosus muscle of children with cerebral palsy. Dev Med Child Neurol 46 (Suppl. 98): 8.
34. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. (2005) Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53: 407-415.